Alpine Immune Sciences

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Alpine Immune Sciences advances drug pipeline amidst financial challenges

Alpine Immune Sciences shows promise with progress on povetacicept and strategic studies for autoimmune diseases.
While facing financial challenges, the company's strong cash position and collaborations offer growth opportunities.
Effective cost management, successful clinical trials, and market expansion are crucial for Alpine's future success.

Alpine Immune Sciences reports robust 2023 performance and clinical advancements

Alpine Immune Sciences demonstrated strong financial performance and promising clinical advancements in 2023.
The company's focus on povetacicept as a disease-modifying therapy presents significant opportunities for growth.
Challenges lie in maintaining clinical momentum and managing expenses effectively to sustain progress.
Overall, Alpine's strategic initiatives position it well for continued success in the biopharmaceutical space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alpine Immune Sciences is a clinical-stage biopharmaceutical business focused on researching and developing protein-based immunotherapies to treat autoimmune and inflammatory disorders. Its strategy incorporates a patented scientific platform for transforming native immune system proteins into differentiated, multi-targeted therapies. ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc.

Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2022 financial results on Thursday, March 23, 2023, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.

Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will present a corporate overview and host investor meetings at the SVB Securities Global Biopharma Conference and present on Thursday, February 16, 2023, at 12:00 p.m. ET/9:00 a.m. PT.

Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference

SEATTLE--( BUSINESS WIRE )--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022, at 12:35 p.m. ET/9:35 a.m. PT.

Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference

Alpine Immune Sciences, Inc. (NASDAQ:ALPN ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Peng - President, Head of R&D Andrew Sandler - CMO Paul Rickey - CFO Operator Welcome to the Alpine Immune Sciences Third Quarter Earnings Call. Currently all participants are in a listen-only mode.

Alpine Immune Sciences, Inc. (ALPN) Q3 2022 Earnings Call Transcript

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -320% and 59.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Alpine Immune Sciences, Inc. (ALPN) Reports Q3 Loss, Misses Revenue Estimates

SEATTLE--( BUSINESS WIRE )--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, after the close of market.

Alpine Immune Sciences to Report Third Quarter 2022 Financial Results

Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength?

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today presented a poster at the American Society of Nephrology Kidney Week 2022 Meeting highlighting updated clinical data from RUBY-1, a phase 1 healthy volunteer (HV) study of ALPN-303, a dual B cell cytokine antagonist being developed for multiple B cell and/or autoantibody-related diseases.

Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have a poster presentation for ALPN-303's phase 1 study (RUBY-1) at the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition, December 10-13, 2022.

Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alpine Immune Sciences, Inc. (ALPN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Alpine Immune Sciences, Inc. (ALPN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 23.2% in 4 Weeks, Here's Why the Trend Might Reverse for Alpine Immune Sciences, Inc. (ALPN)

The recent termination of ALPN-202 trials due to another patient's death caused the share price to plummet. While this was anticipated, I believe that the market has overreacted due to several reasons.

Alpine Immune Sciences: ALPN-202 May Be Dead, But The Company Isn't

The second patient death prompted Alpine to terminate any future development of davoceticept. It's prudent that Alpine stopped unfruitful developments early on to focus on lower-hanging fruits.

Alpine: Ramifications Of The Davoceticept Termination

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have poster presentations for ALPN-303's phase 1 study (RUBY-1) at upcoming scientific conferences.

Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company has voluntarily terminated enrollment in both clinical studies involving davoceticept (ALPN-202), an investigational CD28 costimulator and dual checkpoint inhibitor, including the NEON-1 study of davoceticept as monotherapy and the NEON-2 study of davoceticept i

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 13,606,000 shares of its common stock pursuant to its existing shelf registration statement. The shares of common stock are being offered at a public offering price of $7.35 per share. The gross proceeds to Alpine from the of

Alpine Immune Sciences Announces Pricing of $100 Million Public Offering

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced clinical updates from two wholly owned programs, ALPN-303 and davoceticept. A broad development plan for ALPN-303 will be presented, including a proof-of-concept phase 2 study in systemic lupus erythematosus (SLE) and basket studies in renal, hematologic, and dermatol

Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced members of its management team will participate at the following investor conferences in September 2022. H.C. Wainwright 24th Annual Global Investment Conference Date: Monday, September 12, 2022 Time: 7:00 a.m. PT/10:00 a.m. ET Event: Corporate Presentation & One-o

Alpine Immune Sciences Announces Participation in September Investor Conferences

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that it will host an R&D Day featuring clinical data presentations on ALPN-303, a potentially best-in-class dual B cell cytokine antagonist being developed for the treatment of B cell mediated inflammatory and autoimmune diseases, and davoceticept (ALPN-202), a con

Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced that, in connection with the previously announced appointment of Andrew S. Sandler, M.D. as Chief Medical Officer, it has granted Dr. Sandler an option to purchase 160,000 shares of common stock. The option will vest with respect to 25% of the shares underlying the option on the

Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D.

Alpine Immune Sciences, Inc. (ALPN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Alpine Immune Sciences, Inc. (ALPN) Moves to Buy: Rationale Behind the Upgrade

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022. “We are pleased with our productive second quarter that included the presentation of encouraging clinical data across our pipeline of novel autoimmune and immuno-oncology cand

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Evotec SE

JUST - EVOTEC BIOLOGICS WILL APPLY ITS FULLY INTEGRATED TECHNOLOGY PLATFORM TO DEVELOP AN OPTIMISED COMMERCIAL PROCESS FOR ALPN-303, A DUAL BAFF/APRIL INHIBITOR FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER AUTOIMMUNE AND INFLAMMATORY DISEASES HAMBURG, GERMANY & SEATTLE, WA / ACCESSWIRE / August 10, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for the treatment of systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. The contract is a continuation of their first-in-human program initiated in 2020 in which Just - Evotec Biologics delivered drug substance materials using their J.DESIGN continuous manufacturing platform for Alpine's ongoing Phase I study and anticipated Phase II studies of ALPN-303.

News for Alpine Immune Sciences Stock (ALPN)